UNIT 20.4 The P815 Mastocytoma Tumor Model

  1. Thomas F. Gajewski1,
  2. Mary A. Markiewicz1,
  3. Catherine Uyttenhove2

Published Online: 1 MAY 2001

DOI: 10.1002/0471142735.im2004s43

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Gajewski, T. F., Markiewicz, M. A. and Uyttenhove, C. 2001. The P815 Mastocytoma Tumor Model. Current Protocols in Immunology. 43:20.4:20.4.1–20.4.18.

Author Information

  1. 1

    The University of Chicago, Chicago, Illinois

  2. 2

    Ludwig Institute for Cancer Research, Brussels, Belgium

Publication History

  1. Published Online: 1 MAY 2001
  2. Published Print: JUN 2001


This unit presents an experimental tumor model which has led to pivotal advances in tumor immunology culminating in the preclinical development of human cancer vaccines for melanoma. The model employs the use of the P815 mastocytoma cell line. Although the P815 cell line belongs to the mast cell lineage, it offers several advantages for in vivo experimentation of the tumor-host relationship. It grows progressively in the majority of syngeneic DBA/2 mice and can be implanted either intraperitoneally or subcutaneously. Moreover, immunogeneic variants have been created yielding tumors that are spontaneously rejected BB a behavior that has provided a context in which to study the immunologically relevant molecules and cells that dictate a successful anti-tumor response.